|
Name: Lasmiditan [2,4,6-trifluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridine-2-yl-benzamide]
Type: Serotonin receptor agonist
AKA: Reyvow
![Lasmiditan [2,4,6-trifluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridine-2-yl-benzamide] image](https://grammasearch.com/dev/v2/aiimages/lasmiditan_%5B2%2C4%2C6-trifluoro-n-%286-%281-methylpiperidine-4-carbonyl%29pyridine-2-yl-benzamide%5D.png)
|
|
II. Natural Derivative
Synthetic substance, no natural derivative
 |
|
III. Chemical Profile (IUPAC name)
![Lasmiditan [2,4,6-trifluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridine-2-yl-benzamide] image](/dev/v2/pages/pubchem_images/125395235.png)
|
|
IV. History
Lasmiditan, a novel medication, was first introduced in the late 2010s. It was developed for the treatment of acute migraine attacks. The compound represents a new class of migraine medication, offering a targeted approach to migraine relief. Lasmiditan's introduction reflects advancements in migraine treatment and its focus on reducing migraine symptoms with fewer side effects.
|
|
V. Legal Information
Lasmiditan is a medication used for the treatment of migraines. It is controlled under pharmaceutical regulations to manage its medical use and prevent misuse. [Source: UNODC].
US Federal Schedule - V
Schedule V drugs, substances, or chemicals are defined as drugs with lower potential for abuse than Schedule IV and consist of preparations containing limited quantities of certain narcotics. Schedule V drugs are generally used for antidiarrheal, antitussive, and analgesic purposes. Some examples of Schedule V drugs are: cough preparations with less than 200 milligrams of codeine or per 100 milliliters (Robitussin AC), Lomotil, Motofen, Lyrica, Parepectolin.
Key US Federal Policies:
Controlled Substances Act. Public Law: Public Law 91-513 (text can be found on GovInfo) (https://www.dea.gov/drug-information/csa). Date enacted: October 27, 1970.
|
|
VI. Physical Effects
Lasmiditan is a medication used for acute migraine treatment. It acts as a selective serotonin receptor agonist, with effects that include headache relief. Short-term use is effective for migraines, but long-term safety data is limited. Overdose risks are low, but excessive use may lead to side effects like dizziness and nausea. Safe use involves prescribed dosing. Recent research highlights its efficacy in treating migraines.  |
|
VII. Psychological Effects
Lasmiditan is a selective 5-HT1F receptor agonist used to treat migraines. It primarily affects serotonin receptors in the brain, reducing migraine symptoms without affecting other serotonin pathways. Immediate effects include relief from migraine symptoms and improved mood. Long-term use is generally well-tolerated but may occasionally lead to mild dizziness or somnolence. Recent studies suggest lasmiditan is effective in reducing migraine frequency with fewer side effects compared to traditional treatments.
 |
|
VIII. Culture
Lasmiditan is a novel antimigraine medication acting as a serotonin receptor agonist, classifying it as a downer. Short-term use reduces migraine symptoms, while long-term use is still under study. Overdose risks are low but can cause severe dizziness and sedation. Safe dosages are medically prescribed, typically 50-100 mg as needed. Recent research supports its efficacy in migraine management. Physical effects include drowsiness, dizziness, and potential coordination issues.
 |